As we age, the outcome of our decisions become more critical. Retirees over 65 who are contemplating just one more home transition must consider a wide range of topics before deciding to sell their home. In this presentation, you will learn how the areas of your: finances, health, family, trust, and real estate are all holistically interconnected You will evaluate where you currently stand, envision your future, learn about important red flags and ultimately create a Homeowner Flight-Plan.
Brian Schwatka, Realtor and Transition Specialist
Brian Schwatka has been a Realtor and Transition Specialist since 2004. He helps homeowners of all ages and is also a Seniors Real Estate Specialist as well as a Certified Seniors Advisor. During his career in Real Estate, Brian has consistently been in the top 5% of all agents in the nation and the top 5% World Wide. Brian is also the creator of the “Stay or Go Homeowner” system which has helped hundreds of homeowners decide if they should stay in their homes or make a transition to a new home. He offers live workshops, on-line videos and personal consultations in the areas of Real Estate, Financial Planning, Estate Planning, Taxes, Downsizing and more. Brian’s goal is to give his clients clarity, certainty and confidence so they can save time, money and frustration.
Navigating Biotech Investing in 2020
The Medical Technology Stock Letter has a proven track record of identifying Biotech winners like last year’s top pick, MDCO. We can help you navigate the corona virus and election year drug pricing rhetoric to find more Biotech winners. Specific discussion points:
1. Biotech fundamentals have never been better; perfect storm of technology, cash, and an accommodating FDA combined with ever growing demand for drugs.
2. COVID-19, our experience with H1N1, Ebola and SARS helps our subscribers understand the real threats and potential investment opportunities.
Biotech is part of the Solution to COVID-19 and any other future disease threats
John McCamant, Editor, Medical Technology Stock Letter
John McCamant has more than 25 years of experience in biotechnology investing. He is frequently quoted in the financial press. Before becoming editor of the Medical Technology Stock Letter, he worked as an equities analyst in the investment banking and venture capital industry.